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The dose-response relations varied between patients with or without RP. In patients who developed RP, perfusion reduction was larger in 20-40 Gy dose bin at 3 months FU (p=0.04), and in >60 Gy dose bin at 6 months (p=0.03), compared to those without the complication. Low dose regions, on the contrary, revealed larger perfusion increase at 12 months FU in the patients with RP (p=0.002).
Conclusion:
Progressive dose dependent perfusion loss was seen on SPECT up to 12 months following IMRT. Patients with radiation pneumonitis demonstrate a larger perfusion loss in the high dose regions, as well as relatively larger perfusion increase in regions receiving low dose, possibly due to function being shunted to these areas.
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A novel concept to tumour targeting: inverse dose-painting or targeting the "Low uptake drug volume" A. Yaromina 1 MAASTRO clinic, Radiation Oncology, Maastricht, The Netherlands 1 , M. Granzier 1 , W. Van Elmpt 1 , R. Biemans 1 , N. Lieuwes 1 , L. Dubois 1 , P. Lambin 1 Purpose or Objective: There are several potentially radioresistant targets for dose escalation in dose-painting apporoach. Among them tumor hypoxia is a very attractive target. However, 2-3 times higher radiation dose is required to overcome hypoxia-mediated radioresistance in tumors, which is clinically difficult to achieve due to normal tissues constraints. Therefore, we propose a novel treatment approach to combine 1) targeting hypoxic tumor cells with a hypoxia-activated prodrug (HAP) TH302 and 2) at the same time use inverse radiation dose-painting strategy to boost tumor subvolumes with no/low drug uptake. We tested this approach in a rat rhabdomyosarcoma model using 18F-HX4 hypoxia tracer, which is a surrogate of TH302 accumulation in a tumor.
Material and Methods:
A clinical PET/CT scanner was used to evaluate 18F-HX4 uptake 3 hrs post injection. Low or high drug uptake volume (LDUV or HDUV) was defined as 40% of the GTV with the highest or the lowest 18F-HX4 uptake, i.e. TH302 accumulation. Within 24 hrs after PET/CT animals (n=9) received either a single dose radiotherapy (RT) uniformly or a dose-painted non-uniform irradiation with 50% higher dose to LDUV or to HDUV. Mean dose in uniform RT was 18.5 Gy similarly to the mean dose in DUV. Mean dose to the GTV in the non-uniform RT scenario was 14.9 Gy. Treatment plans were created using Eclipse treatment planning system. Animals were irradiated on a TrueBeam High Definition 120 Leaf MLC linac. Tumor response was quantified as time required to reach 3-times starting tumor volume (TGTV3).
Results:
Non-uniform RT with radiation boost to tumor subvolumes with low TH302 uptake (LDUV) was much more effective than the same dose escalation to subvolumes with high drug uptake (Fig. 1) . Noteworthy, dose escalation to LDUV was as effective as uniform RT with 3.6 Gy higher mean dose to GTV. Fig. 1 .Time to reach 3-times starting tumor volume (TGTV3) after uniform RT or non-uniform RT with dose escalation to tumor volume with high drug uptake (HDUV) or low drug uptake (LDUV). Mean dose (Dm) to GTV is indicated.
Conclusion:
The results of this pilot study support targeted dose escalation in non-hypoxic tumor subvolumes with no/low accumulation of hypoxia-activated prodrugs, which requires further confirmation. This strategy appears to be as effective as a uniform dose escalation of the entire GTV but with greater capacity to spare normal tissues. It is expected that this approach of inverse dose-painting can be combined with other imageable cytotoxic drugs, which warrants further investigations. The implicit concept behind the title of this lecture concerns the role of "quantitative" data-driven approaches in assessing dose-volume effects in normal tissues in the era of "high-tech" radiotherapy and integration of "omics". The continuously growing literature regarding dose-volume relationships indirectly reflects the need of improving and refining our knowledge in this field [1] . This seems to be particularly urgent in a number of clinically relevant situations such as, for instance, heart, bowel and bladder. However, the impact of the above mentioned elements ("high-tech & "omics") on the research issues of this field is increasingly relevant and claims for the development of new research lines and methods that will shortly be overviewed in the lecture.
